IMMX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Immix Biopharma, Inc. (IMMX) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has promising prospects in its lead drug candidate NXC-201, the technical indicators, financial performance, and lack of proprietary trading signals suggest waiting for a more favorable entry point.
The MACD is negatively expanding (-0.275), RSI is neutral at 37.555, and moving averages are converging, indicating no clear upward momentum. The stock is trading near its support level (S1: 8.415), but there is no strong bullish signal.
Analyst ratings are optimistic with multiple firms initiating coverage with 'Overweight' or 'Outperform' ratings and price targets significantly above the current price. The company's lead candidate, NXC-201, has shown encouraging clinical data and has the potential to address an unmet medical need in AL amyloidosis.
The stock has experienced a recent price decline (-2.13% in the regular market and -3.70% pre-market). Technical indicators do not show strong bullish momentum, and there is no recent congress trading data or significant insider/hedge fund activity to suggest confidence from influential investors.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net loss of $10.69M, though net income improved by 122.11% YoY. EPS improved to -0.27 (up 68.75% YoY), but the company remains unprofitable.
Analysts are bullish with price targets ranging from $14 to $23, citing the potential of NXC-201 to address a $1B+ market opportunity. However, these targets are contingent on successful clinical trials and regulatory approval.
